HIV-1-infection Active Not Recruiting Phase 3 Trials for Dolutegravir (DB08930)

Also known as: HIV -1 Infection / HIV1 Infection / HIV-I Infection / HIV 1 Infection / Human Immunodeficiency Virus Type 1 (HIV-1) Infection / Human Immunodeficiency Virus I Infection / Infection, Human Immunodeficiency Virus I / HIV-1 Infections / HIV-1 Infection / [X]Human immunodeficiency virus disease (disorder) / Human immunodeficiency virus [HIV] disease / [X]Unspecified human immunodeficiency virus [HIV] disease (disorder) / HIV disease / (AIDS) or (HIV infection) / HTLV-III/LAV infection -RETIRED- / HIV infection NOS / Human immunodeficiency virus syndrome / Human immunodeficiency virus infection, unspecified / HIV Infections / HIV infection / Human immunodeficiency virus infection (disorder)

IndicationStatusPhase
DBCOND0054009 (HIV-1-infection)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02607956Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsTreatment
NCT02607930Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naïve AdultsTreatment
NCT03122262ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral TherapyTreatment
NCT02987530National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) InfectionTreatment
NCT03110380Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Adults Who Are Virologically SuppressedTreatment
NCT03249181Dolutegravir in Pregnant HIV Mothers and Their NeonatesTreatment